Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Mar 25, 2025, 17:31 ET

      Share this article

      Share this article


      ROCKLATAN/ROCLANDA holds significant market potential for treating open-angle glaucoma (OAG) and ocular hypertension by effectively reducing IOP. This fixed-dose combination merges the benefits of a Rho kinase inhibitor and a prostaglandin F2α analog, providing superior efficacy compared to monotherapies.

      LAS VEGAS, March 25, 2025 /PRNewswire/ -- DelveInsight's "ROCKLATAN/ROCLANDA Market Size, Forecast, and Market Insight Report" highlights the details around ROCKLATAN/ROCLANDA, which is a fixed-dose combination of a Rho kinase inhibitor and a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of ROCKLATAN/ROCLANDA. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

      Alcon/Santen's ROCKLATAN/ROCLANDA (netarsudil and latanoprost ophthalmic solution) Overview

      ROCKLATAN/ROCLANDA (netarsudil and latanoprost ophthalmic solution) 0.02% and 0.005% is a prescription drug used to lower elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Its effectiveness is thought to result from the combined action of a Rho kinase inhibitor and a prostaglandin F2α analog in a fixed-dose formulation.

      Aerie Pharmaceuticals originally developed ROCKLATAN/ROCLANDA, and Alcon acquired the company in 2022. Santen holds the rights to commercialize the drug in most markets outside the US, where it is sold as ROCKLATAN in the US and as ROCLANDA in Europe. The medication combines netarsudil and latanoprost, both of which help reduce elevated IOP. High IOP is a significant risk factor for glaucomatous visual field loss, as higher IOP increases the chance of optic nerve damage and vision loss. ROCKLATAN is believed to lower IOP by improving the outflow of aqueous humor.

      Drug Name

      ROCKLATAN/ROCLANDA (netarsudil and latanoprost ophthalmic solution)

      Approved Year

      US: 2019, EU: 2021

      Molecule type

      Small molecule

      Developer

      Alcon/Santen

      Indication

      Reduction of elevated IOP in patients with OAG or ocular hypertension

      Mechanism of action

      Prostaglandin F2α agonists and Rho kinase inhibitors

      Route of administration

      Topical ophthalmic

      Learn more about ROCKLATAN/ROCLANDA projected market size for open-angle glaucoma and ocular hypertension @ ROCKLATAN/ROCLANDA Market Potential 

      Ocular hypertension (OHT) refers to any condition where intraocular pressure (IOP) surpasses 21 mm Hg, which is considered the upper limit of normal eye pressure. OHT occurs when the eye's drainage system functions poorly, causing pressure to build up. This condition is significant because it can be an early indicator of glaucoma, a serious eye disease that may lead to permanent vision loss. Delveinsight estimates that around 9 million OHT cases were reported in the United States in 2023, with the number expected to increase by 2034.  

      Current OHT treatments fall into several categories, including prostaglandin analogs, beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, sympathomimetics, and miotics. Key approved treatments like iDoseTR, OMLONTI, and ROCKLATAN/ROCLANDA are shaping the US ocular hypertension market, which is projected to grow further by 2034. This expansion will likely be driven by the introduction of innovative therapies expected to transform the treatment landscape.

      Discover more about the ocular hypertension market in detail @ Ocular Hypertension Market Report

      Emerging Competitors of ROCKLATAN/ROCLANDA

      IOP in patients with OAG or ocular hypertension is a growing concern, and there is a need for the development of new drugs. The limited arsenal of effective drugs poses a significant challenge in managing the disorder. Some of the drugs in the pipeline include PER-001 (Perfuse Therapeutics) and AGN-193408 (AbbVie), among others. 

      PER-001 is an innovative, first-in-class small molecule endothelin receptor antagonist. It is formulated as a 4 mm bioerodible cylindrical implant, designed for intravitreal administration using a single-use, 25-gauge applicator. The implant is engineered to deliver a sustained release of PER-001 into the vitreous cavity of the eye for up to six months. 

      The other companies that are developing drugs for open-angle glaucoma or ocular hypertension include TearClear (TC-002 (latanoprost ophthalmic solution 0.005%)), Betaliq (BTQ-1902), Nicox Ophthalmics (NCX 470), Santen Inc./Ono Pharmaceutical (Sepetaprost), Sun Pharma Advanced Research Company/Visiox Pharma (PDP-716), Santen Pharmaceutical (STN-1012600), and others.

      The anticipated launch of these therapies will give a boost to the open-angle glaucoma or ocular hypertension market, but at the same time, it will also create a competitive space between the already approved ROCKLATAN/ROCLANDA and these emerging therapies. 

      To know more about the number of competing drugs in development, visit @ ROCKLATAN/ROCLANDA Market Positioning Compared to Other Drugs

      Key Milestones of ROCKLATAN/ROCLANDA

      • In November 2022, Alcon completed the acquisition of Aerie Pharmaceuticals and added ROCKLATAN and RHOPRESSA and several clinical and preclinical ophthalmic pharmaceutical candidates to its portfolio.
      • In December 2021, Santen Pharmaceutical announced a global expansion of its exclusive development and commercialization agreement with Aerie Pharmaceuticals for ROCKLATAN/ROCLANDA by concluding a new agreement to target additional territories, including Europe and several other regions.
      • In January 2021, ROCLANDA received marketing authorization in Europe for the reduction of elevated IOP in adult patients with primary OAG or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.
      • In October 2020, Santen and Aerie signed an exclusive development and marketing agreement for ROCKLATAN/ROCLANDA in Japan.
      • In March 2019, the US FDA approved ROCKLATAN as a once-daily IOP-lowering eye drop for patients with OAG or ocular hypertension.

      ROCKLATAN Patent Details

      ROCKLATAN is fully protected by multiple patents, which expire in 2034 in the US and in 2037 in Japan.

      Discover how ROCKLATAN/ROCLANDA is shaping the open-angle glaucoma and ocular hypertension treatment landscape @ ROCKLATAN Eye Drops

      ROCKLATAN/ROCLANDA Market Dynamics

      ROCKLATAN's fixed-dose combination of a Rho kinase inhibitor and a prostaglandin F2α analogue sets it apart from other ophthalmic solutions, potentially offering a more targeted approach with reduced side effects. Its dual mechanism of action enhances IOP reduction, making it an attractive option for patients with OAG or ocular hypertension who require more aggressive treatment. Furthermore, its once-daily dosing regimen may improve patient adherence, a crucial factor in chronic eye conditions.

      However, ROCKLATAN still carries the risk of adverse effects such as akathisia, sedation, and extrapyramidal symptoms, which could limit its adoption among certain patient groups. Additionally, the ophthalmic drug market is highly competitive, with alternative therapies emerging that may offer comparable or superior efficacy. Pricing pressures, insurance coverage challenges, and physician preferences for established treatments could further hinder ROCKLATAN's growth. Despite these challenges, there may be opportunities to explore additional indications or combination therapies to expand ROCKLATAN's market potential.

      Dive deeper to get more insight into ROCKLATAN/ROCLANDA's strengths & weaknesses relative to competitors @ ROCKLATAN/ROCLANDA Market Drug Report

      Table of Contents

      1

      Report Introduction

      2

      ROCKLATAN/ROCLANDA: Alcon/Santen

      2.1

      Product Overview

      2.2

      Other Development Activities

      2.3

      Clinical Development

      2.4

      Clinical Trials Information

      2.5

      Safety and Efficacy

      2.6

      Product Profile

      2.7

      Market Assessment

      2.7.1

      The 7MM Analysis

      2.7.1.1

      Cost Assumptions and Rebate

      2.7.1.2

      Pricing Trends

      2.7.1.3

      Analogue Assessment

      2.7.1.4

      Launch Year and Therapy Uptake

      2.7.2

      The United States Market Analysis

      2.7.3

      EU4 and the United Kingdom Market Analysis

      2.7.3.1

      Germany

      2.7.3.2

      France

      2.7.3.3

      Italy

      2.7.3.4

      Spain

      2.7.3.5

      UK

      2.7.4

      Japan Market Analysis

      2.8

      Market Drivers

      2.9

      Market Barriers

      2.10

      SWOT Analysis

      3

      Key Cross of Marketed Competitors of ROCKLATAN/ROCLANDA

      4

      Key Cross of Emerging Competitors of ROCKLATAN/ROCLANDA

      Related Reports

      Ocular Hypertension Market

      Ocular Hypertension Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ocular hypertension companies including Kubota Vision Inc., Otsuka Pharmaceuticals Co. Ltd, Theratocular Biotek Co., Novotech Pty Limited, Metagone Biotech Inc., Future Medicine, Novartis, Chakshu Research Inc., Jenivision Inc., Mati Therapeutics Inc., QLT Inc., Santen Inc., AbbVie, Aerie Pharmaceuticals, Qlaris Bio Inc., Nephron Pharmaceuticals, Corporation, Envisia Therapeutics, among others.

      Ocular Hypertension Pipeline

      Ocular Hypertension Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ocular hypertension companies, including Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, LLC, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, Whitecap Biosciences, pH Pharma, Chong Kun Dang, Laboratoires Thea,  among others.

      Open-Angle Glaucoma Market

      Open-Angle Glaucoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key open-angle glaucoma companies including Aerie Pharmaceuticals, Alcon Research, Allergan, Bausch and Lomb, Chong Kun Dang Pharmaceutical, D.Western Therapeutics Institute (DWTI)/Kowa LTD., Envisia Therapeutics, Laboratorios Sophia S.A de C.V., Merck Sharp & Dohme Corp., Nicox Ophthalmics, Novartis/Alcon Research, Ocuphire Pharma, Ono Pharmaceutical, Peregrine Ophthalmic, Perrigo Company, Santen Inc., Santen Pharmaceutical, Sun Pharma Advanced Research Company Limited (SPARC), Sylentis, and Ube Industries, among others.

      Open-Angle Glaucoma Pipeline

      Open-Angle Glaucoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key open-angle glaucoma companies, including Qlaris Bio, Ocular Therapeutix, SALVAT, Aerpio Pharmaceuticals, Ocularis Pharma, PolyActiva, AbbVie, Annexon, Skye Bioscience, GrayBug, Quark Pharmaceuticals, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us
      Shruti Thakur  
      [email protected]  
      +14699457679

      Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.